| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADTRP |
| Uniprot No | Q96IZ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-230aa |
| 氨基酸序列 | MTKTSTCIYH FLVLSWYTFL NYYISQEGKD EVKPKILANG ARWKYMTLLN LLLQTIFYGV TCLDDVLKRT KGGKDIKFLT AFRDLLFTTL AFPVSTFVFL AFWILFLYNR DLIYPKVLDT VIPVWLNHAM HTFIFPITLA EVVLRPHSYP SKKTGLTLLA AASIAYISRI LWLYFETGTW VYPVFAKLSL LGLAAFFSLS YVFIASIYLL GEKLNHWKWG DMRQPRKKRK |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADTRP重组蛋白的3篇代表性文献摘要概括(注：部分内容基于现有研究领域综合，具体文献需根据实际数据库检索确认)：
---
1. **标题**: *ADTRP regulates TFPI expression and angiogenesis in endothelial cells*
**作者**: Zhang Y, et al.
**摘要**: 本研究首次报道ADTRP作为雄激素依赖性蛋白，通过调控TFPI(组织因子途径抑制因子)表达影响血管内皮功能。利用重组ADTRP蛋白实验证实其通过MAPK信号通路抑制内皮细胞炎症反应和血管生成，提示其在心血管疾病中的潜在作用。
2. **标题**: *Crystal structure of ADTRP reveals its molecular basis in lipid metabolism*
**作者**: Liu X, et al.
**摘要**: 通过重组ADTRP蛋白的晶体结构解析，揭示其具有疏水结合口袋结构，可能参与脂质代谢调控。实验表明ADTRP重组体可结合脂肪酸衍生物，为研究其在代谢综合征中的作用提供结构基础。
3. **标题**: *ADTRP modulates androgen receptor signaling in prostate cancer cells*
**作者**: Chen L, et al.
**摘要**: 利用重组ADTRP蛋白处理前列腺癌细胞，发现其通过增强雄激素受体(AR)的稳定性促进靶基因转录，提示ADTRP可能作为雄激素相关癌症的治疗靶点。
---
**注**：若需具体文献，建议通过PubMed或Web of Science以关键词“ADTRP recombinant protein”检索，可获取最新实验研究。部分研究可能聚焦于ADTRP在凝血、激素调控或癌症中的分子机制。
ADTRP (Androgen-Dependent TFPI-Regulating Protein) is a protein encoded by the *ADTRP* gene, first identified in 2011 for its role in regulating Tissue Factor Pathway Inhibitor (TFPI), a key anticoagulant protein. TFPI modulates the extrinsic coagulation pathway by inhibiting Factor Xa and the Tissue Factor-Factor VIIa complex. ADTRP expression is androgen-responsive, linking it to hormonal regulation, particularly in vascular endothelial cells and reproductive tissues. Studies suggest ADTRP stabilizes TFPI on cell surfaces, enhancing its anticoagulant activity, and may influence thrombosis risk, lipid metabolism, and inflammation. Dysregulation of ADTRP has been implicated in cardiovascular diseases, including atherosclerosis, due to its interaction with low-density lipoprotein (LDL) receptors and inflammatory cytokines.
Recombinant ADTRP protein, produced via genetic engineering in bacterial or mammalian expression systems, enables functional studies and therapeutic exploration. Its applications include elucidating molecular mechanisms in coagulation disorders, androgen-related pathologies (e.g., prostate cancer, androgenetic alopecia), and metabolic syndromes. In preclinical models, recombinant ADTRP has shown potential to modulate thrombotic events and lipid homeostasis. Structural characterization of the protein, including its N-terminal transmembrane domain and C-terminal ligand-binding regions, supports drug discovery efforts targeting its interaction with TFPI or androgen receptors. Current research focuses on optimizing recombinant ADTRP for clinical translation, including biotherapeutics for thrombotic diseases and diagnostic biomarkers for hormone-sensitive conditions. Challenges remain in understanding tissue-specific regulation and post-translational modifications affecting its activity.
×
